Molecular, cellular and pharmacological effects of platinum(II) diiodido complexes containing 9-deazahypoxanthine derivatives: A group of broad-spectrum anticancer active agents.

The platinum(II) iodido complexes 1-5 of the general formula cis-[PtI(L)], where L stands for O-substituted 9-deazahypoxanthine derivatives, were prepared and thoroughly characterized by various techniques, including multinuclear 1D and 2D NMR spectroscopy. The complexes were screened for their anticancer potential in vitro on ten human cancer cell lines, concretely breast adenocarcinoma (MCF7), osteosarcoma (HOS), lung carcinoma (A549), cervix epithelioid carcinoma (HeLa), malignant melanoma (G-361), prostate carcinoma (22Rv1, PC-3), hepatocellular carcinoma (HepG2), ovarian carcinoma (A2780) and cisplatin-resistant ovarian carcinoma (A2780R). The complexes exhibited significant wide-spectrum anticancer activity in vitro against all the employed cell lines, with IC≈0.

Structural Diversity of Copper(II) Complexes with 9-Deazahypoxanthine and Their in Vitro SOD-Like Activity.

Two structurally different copper(II) complexes of the compositions [{Cu(9dhx)(H2O)3}2(µ-SO4)2] (1) and [Cu(9dhx)2(H2O)2(NO3)2]·H2O (2), involving 9-deazahypoxanthine (9dhx; 6-oxo-9-deazapurine; 9-deazahypoxanthine), have been prepared and characterized by elemental analysis, infrared and electronic spectroscopy, electrospray ionisation (ESI) mass spectrometry, thermogravimetric (TG) and differential thermal (DTA) analyses, and cyclic voltammetry. The X-ray structures of complexes 1 and [Cu(9dhx)2(H2O)2(NO3)2] (2a) revealed the distorted octahedral geometry in the vicinity of the copper(II) atoms, with the NO5 and N2O4 donor set, respectively. In the dimeric compound 1, the {Cu(9dhx)(H2O)3}2 units are bridged by sulfate groups with the Cu···Cu separation being 5.

Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents.

The gold(I) mixed-ligand complexes involving O-substituted derivatives of 9-deazahypoxanthine (HLn) and triphenylphosphine (PPh3) with the general formula [Au(Ln)(PPh3)] (1-5) were prepared and thoroughly characterized by elemental analysis, FT-IR and multinuclear NMR spectroscopy, ESI+ mass spectrometry, single crystal X-ray (HL5 and complex 2) and TG/DTA analyses. Complexes 1-5 were evaluated for their in vitro antitumor activity against nine human cancer lines, i.e.

[Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7].

Chemotherapy in most patients with AML over 80 years of age is not recommended because their median survival is about 1 month. The aim of our study was to identify patients in this age group who might achieve complete remission with standard dose chemotherapy. We report 9 consecutive patients with de novo AML diagnosed and treated in 1992-2008.

Stereospecific formation of dinuclear vanadium(V) tartrato complexes.

The first dinuclear nonperoxido tartrato complexes of vanadium(V), (NMe(4))(2)[V(2)O(4)((2R,3R)-H(2)tart)(2)] x 6 H(2)O (1), (NMe(4))(2)[V(2)O(2)((2R,3R)-tart)((2S,3S)-tart)] (2), (NEt(4))(2)[V(2)O(2)((2R,3R)-tart)((2S,3S)-tart)] (3) (tart = tartrato(4-) = C(4)H(2)O(6)(4-)) have been prepared from water-ethanol medium and characterized by X-ray structure analysis and spectral methods. The formation of the complexes has been found to be stereospecific; the composition and structure of anions containing one or both enantiomers of the ligand are profoundly different. The structure of anions in 1-3 also differs significantly from the structure of other dinuclear vanadium(V) alpha-hydroxycarboxylato complexes, but, interestingly, the geometry of the [V(2)O(2)((2R,3R)-tart)((2S,3S)-tart)](2-) ion resembles the structure of the [(VO)(2)((2R,3R)-tart)((2S,3S)-tart)](4-) ion which has a vanadium(IV) center.